SE0000540D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0000540D0
SE0000540D0 SE0000540A SE0000540A SE0000540D0 SE 0000540 D0 SE0000540 D0 SE 0000540D0 SE 0000540 A SE0000540 A SE 0000540A SE 0000540 A SE0000540 A SE 0000540A SE 0000540 D0 SE0000540 D0 SE 0000540D0
Authority
SE
Sweden
Prior art keywords
new compounds
compounds
new
formula
Prior art date
Application number
SE0000540A
Other languages
English (en)
Swedish (sv)
Inventor
Eifion Phillips
Richard Schmiesing
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0000540A priority Critical patent/SE0000540D0/xx
Publication of SE0000540D0 publication Critical patent/SE0000540D0/xx
Priority to ARP010100628A priority patent/AR029798A1/es
Priority to IL15054401A priority patent/IL150544A0/xx
Priority to PT01904770T priority patent/PT1259508E/pt
Priority to SK1179-2002A priority patent/SK11792002A3/sk
Priority to EP01904770A priority patent/EP1259508B1/en
Priority to CA002397233A priority patent/CA2397233A1/en
Priority to CNB018049362A priority patent/CN100345847C/zh
Priority to HK03102250.8A priority patent/HK1050007B/en
Priority to HU0301069A priority patent/HUP0301069A3/hu
Priority to AT01904770T priority patent/ATE252099T1/de
Priority to AU32594/01A priority patent/AU782693B2/en
Priority to SI200130060T priority patent/SI1259508T1/xx
Priority to KR1020027010731A priority patent/KR100769394B1/ko
Priority to BR0108456-9A priority patent/BR0108456A/pt
Priority to TR2004/00072T priority patent/TR200400072T4/xx
Priority to UA2002075475A priority patent/UA73540C2/uk
Priority to PCT/SE2001/000329 priority patent/WO2001060821A1/en
Priority to PL357565A priority patent/PL202044B1/pl
Priority to RU2002118302/04A priority patent/RU2263114C2/ru
Priority to NZ520094A priority patent/NZ520094A/en
Priority to JP2001560205A priority patent/JP4084570B2/ja
Priority to EEP200200459A priority patent/EE05149B1/xx
Priority to DK01904770T priority patent/DK1259508T3/da
Priority to DE60100996T priority patent/DE60100996T2/de
Priority to MXPA02007543A priority patent/MXPA02007543A/es
Priority to ES01904770T priority patent/ES2208556T3/es
Priority to CZ20022787A priority patent/CZ20022787A3/cs
Priority to MYPI20010711A priority patent/MY123580A/en
Priority to CO01012482A priority patent/CO5280046A1/es
Priority to US10/123,856 priority patent/US7001914B2/en
Priority to ZA200205479A priority patent/ZA200205479B/xx
Priority to BG106977A priority patent/BG106977A/bg
Priority to IS6492A priority patent/IS6492A/is
Priority to NO20023917A priority patent/NO20023917L/no
Priority to US11/325,787 priority patent/US7214688B2/en
Priority to US11/680,930 priority patent/US7491734B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0000540A 2000-02-18 2000-02-18 New compounds SE0000540D0 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE0000540A SE0000540D0 (sv) 2000-02-18 2000-02-18 New compounds
ARP010100628A AR029798A1 (es) 2000-02-18 2001-02-12 Biarilcarboxamidas, su uso en la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios utiles en ese proceso
CZ20022787A CZ20022787A3 (cs) 2000-02-18 2001-02-15 Nové biarylkarboxamidy
UA2002075475A UA73540C2 (en) 2000-02-18 2001-02-15 Diarylcarboxamides
RU2002118302/04A RU2263114C2 (ru) 2000-02-18 2001-02-15 Соединения, лекарственные средства, способы лечения, способ получения соединений
SK1179-2002A SK11792002A3 (sk) 2000-02-18 2001-02-15 Biarylkarboxamidy, spôsob ich prípravy a ich použitie
EP01904770A EP1259508B1 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
CA002397233A CA2397233A1 (en) 2000-02-18 2001-02-15 Biarylcarboxamides
CNB018049362A CN100345847C (zh) 2000-02-18 2001-02-15 新的联芳基甲酰胺
HK03102250.8A HK1050007B (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
HU0301069A HUP0301069A3 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use
AT01904770T ATE252099T1 (de) 2000-02-18 2001-02-15 Biarylcarboxamide
AU32594/01A AU782693B2 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
SI200130060T SI1259508T1 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
KR1020027010731A KR100769394B1 (ko) 2000-02-18 2001-02-15 신규 비아릴카르복스아미드
BR0108456-9A BR0108456A (pt) 2000-02-18 2001-02-15 Composto, uso de um composto, métodos de tratamento ou de profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e de doenças humanas, e ,processo para preparação de um composto
TR2004/00072T TR200400072T4 (tr) 2000-02-18 2001-02-15 Novel Biarylcarboxamides Biarylcarboxamide Nouveaux Biarylcarboxamides
IL15054401A IL150544A0 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
PCT/SE2001/000329 WO2001060821A1 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
PL357565A PL202044B1 (pl) 2000-02-18 2001-02-15 Nowe biarylokarboksyamidy, ich zastosowanie, sposób wytwarzania biarylokarboksyamidów i związki pośrednie
PT01904770T PT1259508E (pt) 2000-02-18 2001-02-15 Novos biarilcarboxamidas
NZ520094A NZ520094A (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
JP2001560205A JP4084570B2 (ja) 2000-02-18 2001-02-15 新規なビアリールカルボキサミド
EEP200200459A EE05149B1 (et) 2000-02-18 2001-02-15 Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
DK01904770T DK1259508T3 (da) 2000-02-18 2001-02-15 Hidtil ukendte biarylcarboxamider
DE60100996T DE60100996T2 (de) 2000-02-18 2001-02-15 Biarylcarboxamide
MXPA02007543A MXPA02007543A (es) 2000-02-18 2001-02-15 Biarilcarboxamidas novedosas.
ES01904770T ES2208556T3 (es) 2000-02-18 2001-02-15 Nuevas biarilcarboxamidas.
CO01012482A CO5280046A1 (es) 2000-02-18 2001-02-16 Agonistas alfa 7 y sus composiciones farmaceuticas
MYPI20010711A MY123580A (en) 2000-02-18 2001-02-16 Novel biarylcarboxamides
US10/123,856 US7001914B2 (en) 2000-02-18 2002-04-15 Compounds
ZA200205479A ZA200205479B (en) 2000-02-18 2002-07-09 Novel biarylcarboxamides.
BG106977A BG106977A (bg) 2000-02-18 2002-08-02 Нови биарилкарбоксамиди
IS6492A IS6492A (is) 2000-02-18 2002-08-08 Ný bíarýlkarboxamíð
NO20023917A NO20023917L (no) 2000-02-18 2002-08-16 Nye biarylkarboksamider
US11/325,787 US7214688B2 (en) 2000-02-18 2006-01-05 Compounds
US11/680,930 US7491734B2 (en) 2000-02-18 2007-03-01 2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide nicotinic acetylcholine receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000540A SE0000540D0 (sv) 2000-02-18 2000-02-18 New compounds

Publications (1)

Publication Number Publication Date
SE0000540D0 true SE0000540D0 (sv) 2000-02-18

Family

ID=20278508

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000540A SE0000540D0 (sv) 2000-02-18 2000-02-18 New compounds

Country Status (33)

Country Link
US (3) US7001914B2 (https=)
EP (1) EP1259508B1 (https=)
JP (1) JP4084570B2 (https=)
KR (1) KR100769394B1 (https=)
CN (1) CN100345847C (https=)
AR (1) AR029798A1 (https=)
AT (1) ATE252099T1 (https=)
AU (1) AU782693B2 (https=)
BG (1) BG106977A (https=)
BR (1) BR0108456A (https=)
CA (1) CA2397233A1 (https=)
CO (1) CO5280046A1 (https=)
CZ (1) CZ20022787A3 (https=)
DE (1) DE60100996T2 (https=)
DK (1) DK1259508T3 (https=)
EE (1) EE05149B1 (https=)
ES (1) ES2208556T3 (https=)
HU (1) HUP0301069A3 (https=)
IL (1) IL150544A0 (https=)
IS (1) IS6492A (https=)
MX (1) MXPA02007543A (https=)
MY (1) MY123580A (https=)
NO (1) NO20023917L (https=)
NZ (1) NZ520094A (https=)
PL (1) PL202044B1 (https=)
PT (1) PT1259508E (https=)
RU (1) RU2263114C2 (https=)
SE (1) SE0000540D0 (https=)
SK (1) SK11792002A3 (https=)
TR (1) TR200400072T4 (https=)
UA (1) UA73540C2 (https=)
WO (1) WO2001060821A1 (https=)
ZA (1) ZA200205479B (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1311505A2 (en) * 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10103954B4 (de) 2001-01-30 2005-10-06 Advalytix Ag Verfahren zur Analyse von Makromolekülen
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
DE10120035B4 (de) 2001-04-24 2005-07-07 Advalytix Ag Verfahren und Vorrichtung zur Manipulation kleiner Flüssigkeitsmengen auf Oberflächen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
BR0212101A (pt) 2001-08-24 2004-08-24 Pharmacia & Up John Company 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
JP2005527472A (ja) * 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
HUP0402289A2 (hu) 2001-10-02 2005-02-28 Pharmacia & Upjohn Company Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
BR0213760A (pt) * 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
US6919359B2 (en) 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
US6951868B2 (en) 2001-11-09 2005-10-04 Pfizer Inc. Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) * 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
AU2003217275A1 (en) * 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
CN1675204A (zh) * 2002-06-10 2005-09-28 拜耳医药保健股份公司 2－杂芳基甲酰胺
EP1542999A1 (en) 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
KR20050085535A (ko) * 2002-12-11 2005-08-29 파마시아 앤드 업존 캄파니 엘엘씨 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법
WO2004064836A2 (en) * 2003-01-22 2004-08-05 Pharmacia & Upjohn Company Llc Treatment of diseases with alpha-7 nach receptor full agonists
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US20050129610A1 (en) * 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
DE10334724A1 (de) * 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
MXPA06007026A (es) * 2003-12-22 2006-08-31 Astrazeneca Ab Ligandos del receptor nicotinico de acetilcolina.
JP2007515481A (ja) * 2003-12-22 2007-06-14 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリンレセプターリガンド
RU2367665C2 (ru) * 2004-02-04 2009-09-20 НьюроСёрч А/С Диазабициклические арильные производные в качестве лигандов никотиновых ацетилхолиновых рецепторов
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP2008544982A (ja) * 2005-06-29 2008-12-11 アストラゼネカ・アクチエボラーグ アルファ７ニコチン性受容体調節剤としてのチオフェン−２−カルボキサミド誘導体
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2488520B1 (en) 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
KR101925971B1 (ko) * 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
KR101928505B1 (ko) 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
HK1219722A1 (zh) 2013-06-21 2017-04-13 Takeda Pharmaceutical Company Limited 1-磺酰基派啶衍生物作为前动力蛋白受体的调节剂
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
FI20145054L (fi) * 2014-01-21 2015-07-22 Tellabs Oy Tiedonsiirtoverkon verkkoelementti
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
KR101623138B1 (ko) 2014-10-28 2016-05-20 한국원자력연구원 베타 아밀로이드 플라크 검출 및 알츠하이머 질환 진단 또는 치료용 조성물
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
FI791491A7 (fi) * 1979-05-10 1981-01-01 Kopo Konepohja Oy Puun palahakkuri.
FR2529548A1 (fr) 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
EP0546181B1 (en) * 1990-08-31 1995-08-02 Nippon Shinyaku Company, Limited Indole derivatives and their use as serotonin antagonists
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
FR2809732B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
FR2809731B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
FR2809730B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
US6884807B2 (en) 2000-12-01 2005-04-26 Neurosearch, A/S 3-substituted quinuclidines and their use as nicotinic agonists
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
JP2007515481A (ja) * 2003-12-22 2007-06-14 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリンレセプターリガンド
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents

Also Published As

Publication number Publication date
SK11792002A3 (sk) 2003-04-01
AU782693B2 (en) 2005-08-18
HK1050007A1 (en) 2003-06-06
AU3259401A (en) 2001-08-27
EE200200459A (et) 2003-12-15
US20070149563A1 (en) 2007-06-28
JP4084570B2 (ja) 2008-04-30
US20060128749A1 (en) 2006-06-15
BG106977A (bg) 2003-05-30
PL202044B1 (pl) 2009-05-29
WO2001060821A1 (en) 2001-08-23
US20030008867A1 (en) 2003-01-09
CN1400973A (zh) 2003-03-05
KR20020072585A (ko) 2002-09-16
UA73540C2 (en) 2005-08-15
NO20023917L (no) 2002-09-16
NZ520094A (en) 2005-01-28
CN100345847C (zh) 2007-10-31
CA2397233A1 (en) 2001-08-23
EP1259508B1 (en) 2003-10-15
MY123580A (en) 2006-06-30
ZA200205479B (en) 2003-12-31
HUP0301069A2 (hu) 2003-08-28
EE05149B1 (et) 2009-04-15
TR200400072T4 (tr) 2004-02-23
US7001914B2 (en) 2006-02-21
KR100769394B1 (ko) 2007-10-22
MXPA02007543A (es) 2002-12-13
PL357565A1 (en) 2004-07-26
RU2263114C2 (ru) 2005-10-27
US7214688B2 (en) 2007-05-08
CZ20022787A3 (cs) 2003-02-12
IL150544A0 (en) 2003-02-12
DE60100996D1 (de) 2003-11-20
BR0108456A (pt) 2003-04-01
HUP0301069A3 (en) 2004-09-28
JP2003523342A (ja) 2003-08-05
IS6492A (is) 2002-08-08
DK1259508T3 (da) 2004-02-16
AR029798A1 (es) 2003-07-16
DE60100996T2 (de) 2004-09-02
US7491734B2 (en) 2009-02-17
ES2208556T3 (es) 2004-06-16
ATE252099T1 (de) 2003-11-15
PT1259508E (pt) 2004-03-31
NO20023917D0 (no) 2002-08-16
EP1259508A1 (en) 2002-11-27
CO5280046A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
SE0000540D0 (sv) New compounds
CY1107634T1 (el) Φαρμακευτικη συνθεση
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
DE60335359D1 (de) Phthalazinonderivate
NO20031001L (no) Polyarylkarboksamider nyttige som lipidsenkende midler
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
CY1113648T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
PT1193270E (pt) Pirrolobenzodiazepinas
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
NO20042534L (no) Forbedringer vedrorende optiske lysgjoringsmidler
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
PT1181294E (pt) Novos derivados e analogos da galantamina
DE69812634D1 (de) Metalloproteinase-inhibitoren
ATE411287T1 (de) Neue metallproteinaseinhibitoren
SE9901077D0 (sv) Novel use
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
MY128164A (en) Compounds
BRPI0416678A (pt) pirazolpirimidinas
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
EE200200389A (et) Imidasooli uued derivaadid
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
NO20024679D0 (no) Krystallinsk farmasöytikum